Format

Send to

Choose Destination
J Mol Cell Cardiol. 2017 Jun;107:41-51. doi: 10.1016/j.yjmcc.2017.04.004. Epub 2017 Apr 27.

Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice.

Author information

1
Systems Biology Center, National Heart Lung and Blood Institute, NIH, Bethesda, MD, United States.
2
Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX, United States.
3
Department of Molecular and Integrative Physiology, United States.
4
Proteomics Core, NHLBI, NIH, Bethesda, MD, United States.
5
Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, United States.
6
University of Cincinnati Cancer Center, Cincinnati, OH, United States.
7
Systems Biology Center, National Heart Lung and Blood Institute, NIH, Bethesda, MD, United States. Electronic address: murphy1@mail.nih.gov.

Abstract

Steroid hormone receptors including estrogen receptors (ER) classically function as ligand-regulated transcription factors. However, estrogens also elicit cellular effects through binding to extra-nuclear ER (ERα, ERβ, and G protein-coupled ER or GPER) that are coupled to kinases. How extra-nuclear ER actions impact cardiac ischemia-reperfusion (I/R) injury is unknown. We treated ovariectomized wild-type female mice with estradiol or an estrogen-dendrimer conjugate (EDC), which selectively activates extra-nuclear ER, or vehicle interventions for two weeks. I/R injury was then evaluated in isolated Langendorff perfused hearts. Two weeks of treatment with estradiol significantly decreased infarct size and improved post-ischemic contractile function. Similarly, EDC treatment significantly decreased infarct size and increased post-ischemic functional recovery compared to vehicle-treated hearts. EDC also caused an increase in myocardial protein S-nitrosylation, consistent with previous studies showing a role for this post-translational modification in cardioprotection. In further support of a role for S-nitrosylation, inhibition of nitric oxide synthase, but not soluble guanylyl cyclase blocked the EDC mediated protection. The administration of ICI182,780, which is an agonist of G-protein coupled estrogen receptor (GPER) and an antagonist of ERα and ERβ, did not result in protection; however, ICI182,780 significantly blocked EDC-mediated cardioprotection, indicating participation of ERα and/or ERβ. In studies determining the specific ER subtype and cellular target involved, EDC decreased infarct size and improved functional recovery in mice lacking ERα in cardiomyocytes. In contrast, protection was lost in mice deficient in endothelial cell ERα. Thus, extra-nuclear ERα activation in endothelium reduces cardiac I/R injury in mice, and this likely entails increased protein S-nitrosylation. Since EDC does not stimulate uterine growth, in the clinical setting EDC-like compounds may provide myocardial protection without undesired uterotrophic and cancer-promoting effects.

KEYWORDS:

Cardiomyocyte; Endothelium; Estrogen receptor; Nitric oxide signaling

PMID:
28457941
PMCID:
PMC5514412
DOI:
10.1016/j.yjmcc.2017.04.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center